Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
J Immigr Minor Health ; 25(5): 1171-1195, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37407884

ABSTRACT

Immigrant and refugee populations face multiple barriers to accessing mental health services. This scoping review applies the (Levesque et al. in Int J Equity Health 12:18, 2013) Patient-Centred Access to Healthcare model in exploring the potential of increased access through virtual mental healthcare services VMHS for these populations by examining the affordability, availability/accommodation, and appropriateness and acceptability of virtual mental health interventions and assessments. A search in CINAHL, MEDLINE, PSYCINFO, EMBASE, SOCINDEX and SCOPUS following (Arksey and O'Malley in Int J Soc Res Methodol 8:19-32, 2005) guidelines found 44 papers and 41 unique interventions/assessment tools. Accessibility depended on individual (e.g., literacy), program (e.g., computer required) and contextual/social factors (e.g., housing characteristics, internet bandwidth). Participation often required financial and technical support, raising important questions about the generalizability and sustainability of VMHS' accessibility for immigrant and refugee populations. Given limitations in current research (i.e., frequent exclusion of patients with severe mental health issues; limited examination of cultural dimensions; de facto exclusion of those without access to technology), further research appears warranted.


Subject(s)
Emigrants and Immigrants , Mental Health Services , Refugees , Humans , Refugees/psychology , Health Services Accessibility , Patient Acceptance of Health Care
3.
J Med Case Rep ; 16(1): 172, 2022 Apr 26.
Article in English | MEDLINE | ID: mdl-35468849

ABSTRACT

BACKGROUND: Our patient presents with a novel presentation of a fungated ulcerated skin lesion as the initial presentation of lung cancer. The literature describes skin metastases from lung cancer as nodular, papular, and zosteriform. Our case is a fungating ulcerated skin lesion which is not widely reported in literature. There is a still a need for more data on the clinical presentation and prognosis of such cases as it will elucidate the diagnostic challenges and treatment management. CASE PRESENTATION: We present a case of a 55 year old Caucasian male with a 60-pack-year smoking history initially presenting with a nodule on his right upper back that quickly fungated and ulcerated requiring surgical excision. Biopsy of both the skin lesion and the lung mass confirmed squamous cell carcinoma (SCC) and the lung mass being the primary tumor. The patient's clinical and functional status severely declined during his hospital stay and was later discharged to hospice without therapeutic intervention. He later expired a month after hospice stay. CONCLUSIONS: Although uncommon, this case clearly illustrates that skin metastases can be the initial finding of primary lung cancer and that not all patients with lung cancer will present with bronchopulmonary symptoms. It also illustrates that a fungating ulcerated lesion can be the initial presentation of lung cancer in addition to nodular, papular, and zosteriform presentations noted in the literature.


Subject(s)
Carcinoma, Squamous Cell , Lung Neoplasms , Skin Neoplasms , Biopsy , Carcinoma, Squamous Cell/pathology , Humans , Lung/pathology , Lung Neoplasms/pathology , Male , Middle Aged , Skin Neoplasms/pathology
4.
Bioorg Med Chem Lett ; 21(9): 2665-9, 2011 May 01.
Article in English | MEDLINE | ID: mdl-21273063

ABSTRACT

Screening of the Merck sample collection identified compound 1 as a weakly potent GPR119 agonist (hEC(50)=3600 nM). Dual termini optimization of 1 led to compound 36 having improved potency, selectivity, and formulation profile, however, modest physical properties (PP) hindered its utility. Design of a new core containing a cyclopropyl restriction yielded further PP improvements and when combined with the termini SAR optimizations yielded a potent and highly selective agonist suitable for further preclinical development (58).


Subject(s)
Diabetes Mellitus, Type 2 , Drug Design , Receptors, G-Protein-Coupled/agonists , Animals , Diabetes Mellitus, Type 2/drug therapy , Ethers, Cyclic/chemical synthesis , Ethers, Cyclic/chemistry , Humans , Mice , Molecular Structure , Stereoisomerism , Structure-Activity Relationship
6.
J Gen Virol ; 84(Pt 2): 361-368, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12560568

ABSTRACT

A novel, experimental subunit human immunodeficiency virus (HIV) vaccine, SFV.HIVA, was constructed. This consists of Semliki Forest virus (SFV), which is a suitable vaccine vector for use in humans, and a passenger gene encoding HIVA, which is an immunogen derived from HIV-1 clade A that is being currently tested in clinical trials of combined DNA- and modified vaccinia virus Ankara (MVA)-vectored vaccines in Oxford (UK) and Nairobi (Kenya). In the mouse, the SFV.HIVA vaccine was highly immunogenic for T cell-mediated immune responses and induced T cell memory that lasted for at least 6 months. SFV.HIVA was also compared to the vaccines currently used in the clinical trials and was shown to be as effective in T cell induction as pTHr.HIVA DNA but less immunogenic than MVA.HIVA. When tested in a prime-boost regimen, SFV.HIVA-induced responses could be boosted by MVA.HIVA. This work is a part of a long-term effort to build a panel of subunit vaccines expressing a common immunogen, which will allow both a direct comparison of various vaccine vectors and combined vaccination regimens in humans and provide more flexibility and/or a potential optimization of vaccinations for individuals based on their pre-existing anti-vector immunity.


Subject(s)
AIDS Vaccines , Drug Design , Genetic Vectors , HIV-1/immunology , Semliki forest virus/genetics , Animals , CD8-Positive T-Lymphocytes/immunology , Cell Line , Female , HIV Infections/immunology , HIV Infections/prevention & control , HIV-1/classification , HIV-1/genetics , Humans , Immunization , Immunization Schedule , Immunization, Secondary , Mice , Mice, Inbred BALB C , Vaccines, Synthetic/immunology , Vaccinia virus/genetics , Vaccinia virus/immunology
7.
Vaccine ; 21(1-2): 108-14, 2002 Nov 22.
Article in English | MEDLINE | ID: mdl-12443668

ABSTRACT

Toxicity, biodistribution and persistence of candidate HIV vaccines pTHr.HIVA, a recombinant DNA, and MVA.HIVA, a recombinant modified vaccinia virus Ankara, were determined in the Balb/c mouse. The mice were injected with either two doses of intramuscular pTHr.HIVA DNA (50 microg each, separated by an interval of 14 days), two doses of intradermal MVA.HIVA (10(6) plaque-forming units each, separated by an interval of 14 days), or a combination of the two vaccines, each given in two doses, in a prime-boost regimen. The study showed no significant toxic effects, either local or systemic, under any of these employed dosing regimens. With the exception of the sites of delivery, the vaccine-derived HIVA DNA sequences were undetectable 5 weeks after the last dosing. Thus, both the vaccines alone and in a combination were considered safe and suitable for the use in phase I trials in humans.


Subject(s)
AIDS Vaccines/toxicity , HIV-1/immunology , Vaccines, DNA/toxicity , AIDS Vaccines/administration & dosage , AIDS Vaccines/immunology , Animals , Female , HIV-1/classification , Kenya , Male , Mice , Mice, Inbred BALB C , Polymerase Chain Reaction , Vaccines, DNA/administration & dosage , Vaccines, DNA/immunology , Vaccinia virus/genetics , Vaccinia virus/immunology
8.
Vaccine ; 20(15): 1995-8, 2002 May 06.
Article in English | MEDLINE | ID: mdl-11983261

ABSTRACT

Without going into the details of the devastation that human immunodeficiency virus (HIV) infection causes especially in the developing world, the best hope for changing the course of this epidemic is development of a safe, effective, accessible prophylactic HIV vaccine. While the inaccessibility of potentially neutralising epitopes on primary HIV isolates has hampered the development of envelope-based vaccines, there is a number of new potent technologies capable of inducing high levels of circulating virus-specific CD8(+) cytotoxic T lymphocytes (CTL). Our original finding that a successive immunisation with DNA and modified vaccinia virus Ankara (MVA) vaccines expressing a common immunogen is a potent way of inducing CD8(+) CTL, which has been since reinforced by us and others, prompted us to test this approach in humans. With the view of proceeding into a high-risk cohort in Kenya for the efficacy trial, we designed the immunogen, termed HIVA, to match the HIV strain responsible locally for over 70% infections. It consists of a consensus clade A gag p24/p17 and a string of clade A-derived CTL epitopes. Pre-clinical studies demonstrated high immunogenicities of both the pTHr.HIVA and MVA.HIVA vaccines. In mice, these induced strong T cells-mediated immune responses which lasted at least 155 days. In rhesus macaques, the prime-boost immunisation elicited T cell responses specific for multiple HIV-derived epitopes. Phase I trials in healthy low-risk volunteers have commenced in Oxford and Nairobi, and the preliminary immunogenicity analysis from the Oxford site indicated that both vaccine components alone induced T cell responses in a majority of volunteers. These results have boosted expectations for the prime-boost vaccinations.


Subject(s)
AIDS Vaccines , HIV-1/immunology , Vaccines, DNA , AIDS Vaccines/genetics , AIDS Vaccines/immunology , Animals , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Clinical Trials, Phase I as Topic , Cohort Studies , Drug Design , Epitopes/genetics , Epitopes/immunology , HIV Antibodies/biosynthesis , HIV Antibodies/immunology , HIV Core Protein p24/genetics , HIV Core Protein p24/immunology , HIV-1/classification , Humans , Immunization, Secondary , Kenya , Macaca mulatta , Mice , Risk Factors , Safety , Simian Immunodeficiency Virus/immunology , Vaccination , Vaccines, DNA/genetics , Vaccines, DNA/immunology , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Vaccinia virus/immunology , Viral Vaccines/genetics , Viral Vaccines/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...